Drug Profile

BBT 021

Alternative Names: BBT-021; Long-acting erythropoietin analog - Bolder BioTechnology

Latest Information Update: 19 Jun 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bolder BioTechnology
Class Antianaemics; Erythropoietins; Recombinant fusion proteins
Mechanism of Action Erythropoietin receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Preclinical Anaemia

Most Recent Events

19 Jun 2023 BBT 021 is still in preclinical development for Anaemia in USA (Parenteral) (Bolder Biotechnology pipeline, June 2023)
28 May 2022 No recent reports of development identified for preclinical development in Anaemia in USA (Parenteral, Injection)
20 May 2020 BBT 021 is available for licensing as of 20 May 2020. http://www.bolderbio.com/

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com